Compare WSC & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSC | PBLS |
|---|---|---|
| Founded | 1944 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2015 | 2026 |
| Metric | WSC | PBLS |
|---|---|---|
| Price | $18.28 | $28.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $26.20 | ★ $41.40 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $2,281,446,000.00 | N/A |
| Revenue This Year | $1.31 | N/A |
| Revenue Next Year | $2.24 | $300.17 |
| P/E Ratio | $45.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.91 | $22.66 |
| 52 Week High | $29.77 | $42.49 |
| Indicator | WSC | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.65 | 47.54 |
| Support Level | $16.57 | $26.42 |
| Resistance Level | $18.76 | $28.48 |
| Average True Range (ATR) | 0.76 | 2.42 |
| MACD | 0.36 | 0.59 |
| Stochastic Oscillator | 83.60 | 71.50 |
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.